Hospitals to receive additional remdesivir allocations

Jun 29, 2020 - 03:11 PM
hhs-health-and-human-services-seal

The Department of Health and Human Services today announced an agreement with drug maker Gilead Sciences to allow U.S. hospitals to purchase up to 500,000 treatment courses of remdesivir through September, which HHS and state health departments will allocate as they did the previous 120,000 treatment courses donated by the drug maker.

Under the agreement, hospitals will pay no more than the wholesale acquisition price for the drug, or $3,200 per treatment course, which AmerisourceBergen likely will ship to them every two weeks. The investigational drug has shown encouraging results treating certain COVID-19 patients in early clinical trials. HHS said the final donated treatment courses will ship today. To make future allocations of remdesivir, HHS will be asking hospitals and health systems to submit data every two weeks. The next data collection will be July 6.

AHA members will receive a Special Bulletin with more details.

Related News Articles

Headline
FDA authorizes combination tests for flu, COVID-19
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…
Headline
CDC: COVID-19 surging across the U.S.
The Centers for Disease Control and Prevention's COVID-19 data tracker shows an 18.1% test positivity rate for the week ending Aug. 10, the highest it has been…
Headline
CDC issues advisory on increased parvovirus B19 cases in the U.S. 
The Centers for Disease Control and Prevention Aug. 13 issued an advisory alerting of an uptick of cases of parvovirus B19 across the U.S. Parvovirus B19 is a…
Blog
RAND 5.0 – The Health Policy Equivalent of Groundhog Day
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
CDC encourages older adults to get additional COVID-19 vaccine dose 
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
NASEM releases evidence review on COVID-19 vaccine safety
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…